4. High homocysteine levels may double Alzheimer's risk.  February 13, 2002.  Report published in the February 14, 2002, issue of The New England Journal of Medicine

High homocysteine levels may double risk of dementia, Alzheimer's disease
People with elevated levels of homocysteine in the blood had nearly double the risk of developing Alzheimer's disease (AD), according to a new report from scientists at Boston University. The findings, in a group of people participating in the long-running Framingham Study, are the first to tie homocysteine levels measured several years before with later diagnosis of AD and other dementias. The report provides some of the most powerful evidence yet of an association between high plasma homocysteine and later, significant memory loss.
 
The relationship between AD and the amino acid homocysteine is of particular interest because blood levels of homocysteine can be reduced, for example, by increasing intake of folic acid (or folate) and vitamins B6 and B12.

The dementia/AD study is being conducted by Philip A. Wolf, M.D., Boston University (BU), and colleagues at BU and Tufts University, who authored the new findings. The study was supported by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).

"The Framingham population gave us the perfect opportunity to look at homocysteine levels in a group of people without memory problems over a period of several years, well before any evidence of dementia," Wolf pointed out. "This is the clearest demonstration yet of the relationship between elevated homocysteine levels and dementia," he noted.

"The evidence is beginning to mount regarding homocysteine's role in dementia," according to Neil Buckholtz, Ph.D., chief of the Dementias of Aging program at the NIA. "The good news is that we may have found a potential risk factor for AD that is modifiable. " Buckholtz noted that the NIA-sponsored Alzheimer's Disease Cooperative Study, a nationwide consortium of research centers, is already planning a clinical trial of folate and vitamins B6 and B12 to test whether reducing homocysteine levels with high doses of these vitamin supplements can slow the rate of cognitive decline in people diagnosed with AD. Wolf and colleagues followed 1,092 people in a "dementia-free" group of the Framingham cohort. Participants in this group, whose average age was 76, were enrolled in the study between 1976 and 1978. Plasma homocysteine levels were measured between 1979 and 1982 and between 1986 and 1990. Researchers also considered age, sex, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B6 and B12 of the participants. Information from the participants was also available on the late-onset AD genetic risk factor APOE-e4.

<< Previous    1...   7  8  [9]  10  11  ...12    Next >>